Lestaurtinib’s antineoplastic activity converges on JAK/STAT signaling to inhibit treatment naïve and therapy resistant forms ovarian cancer

Esther Rodman(Mass General Brigham), John R. Hawse(Mayo Clinic in Arizona)
npj Precision Oncology
July 11, 2025
Cited by 1


Related Papers